NCT06930872View on ClinicalTrials.gov

Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions
Drug Interaction
Interventions
DRUG

Part 1

ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)

DRUG

Part 2

ZYN002 (transdermal), VPA (oral)

Trial Locations (1)

5000

RECRUITING

CMAX Clinical Research, Adelaide

All Listed Sponsors
lead

Harmony Biosciences Management, Inc.

INDUSTRY